In a new note to investors today, an analyst has provided a rating update for the Healthcare company, BriaCell Therapeutics (BCT – Research Report). Analyst Emily Bodnar from H.C. Wainwright remains bullish on the stock and has a $18.00 price target.
According to TipRanks.com, Bodnar has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -9.1% and a 30.5% success rate. Bodnar covers the Healthcare sector, focusing on stocks such as Acrivon Therapeutics, Inc., Gracell Biotechnologies, and TransCode Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for BriaCell Therapeutics with a C$24.47 average price target.
BriaCell Therapeutics’ market cap is currently C$107.4M and has a P/E ratio of -3.84.
BriaCell Therapeutics Corp is an immuno-oncology focused biotechnology company developing targeted and safe approaches for the management of cancer. BriaCell, in collaboration with Incyte Corp., is conducting a Phase I/IIa clinical trial of Bria-IMT, its lead candidate, in a Combination Study with Incyte drugs, INCMGA00012, and epacadostat, in advanced breast cancer. Additionally, it is developing Bria-OTS, off-the-shelf personalized immunotherapy, for advanced breast cancer. Bria-OTS immunotherapy treatments are personalized to match the patient without the need for personalized manufacturing and is designed to produce a potent and selective immune response against the cancer of each patient eliminating the time, expense and complex manufacturing logistics associated with immunotherapies.
The company’s shares closed last Thursday at C$6.95.
Read More on TSE:BCT:
- BriaCell Records New Responder with Remarkable Improvement of “Eye-Bulging” Metastatic Tumor
- BriaCell reports unprecedented activity of its next-gen cancer immunotherapies
- BriaCell Reports Unprecedented Anti-Tumor Activity of its Next Generation Personalized Breast and Prostate Cancer Immunotherapies in Tumor Models at the 2023 SITC Annual Meeting; FDA Greenlights Bria-OTS™ IND
- BriaCell forms medical advisory board
- BriaCell Forms Medical Advisory Board of Distinguished Breast Cancer Specialists to Advance its Lead Oncology Candidate
